Exact Mass: 603.2093284
Exact Mass Matches: 603.2093284
Found 108 metabolites which its exact mass value is equals to given mass value 603.2093284
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N-[(1R)-1-[3-(4-Ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide
Draflazine
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents
(1S,3R,4R,5R)-1-[[(1R,2S)-2-(4-Chlorophenyl)cyclopropyl]methoxy]-3,4-dihydroxy-5-[(Z)-3-imidazo[4,5-b]pyridin-1-yl-3-phenylprop-2-enoyl]oxycyclohexane-1-carboxylic acid
SSR126768
CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9674; ORIGINAL_PRECURSOR_SCAN_NO 9672 CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9690; ORIGINAL_PRECURSOR_SCAN_NO 9685 CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9723; ORIGINAL_PRECURSOR_SCAN_NO 9721 CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9735; ORIGINAL_PRECURSOR_SCAN_NO 9730 CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9704; ORIGINAL_PRECURSOR_SCAN_NO 9702 CONFIDENCE standard compound; INTERNAL_ID 223; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9749; ORIGINAL_PRECURSOR_SCAN_NO 9744
Cys Arg Tyr Tyr
Cys Tyr Arg Tyr
Cys Tyr Tyr Arg
Asp Phe His Trp
Asp Phe Trp His
Asp His Phe Trp
Asp His Trp Phe
Asp Trp Phe His
Asp Trp His Phe
Phe Asp His Trp
Phe Asp Trp His
Phe His Asp Trp
Phe His Trp Asp
Phe Trp Asp His
Phe Trp His Asp
His Asp Phe Trp
His Asp Trp Phe
His Phe Asp Trp
His Phe Trp Asp
His Met Met Trp
His Met Trp Met
His Trp Asp Phe
His Trp Phe Asp
His Trp Met Met
Met His Met Trp
Met His Trp Met
Met Met His Trp
Met Met Trp His
Met Gln Tyr Tyr
Met Trp His Met
Met Trp Met His
Met Tyr Gln Tyr
Met Tyr Tyr Gln
Gln Met Tyr Tyr
Gln Tyr Met Tyr
Gln Tyr Tyr Met
Arg Cys Tyr Tyr
Arg Tyr Cys Tyr
Arg Tyr Tyr Cys
Trp Asp Phe His
Trp Asp His Phe
Trp Phe Asp His
Trp Phe His Asp
Trp His Asp Phe
Trp His Phe Asp
Trp His Met Met
Trp Met His Met
Trp Met Met His
Tyr Cys Arg Tyr
Tyr Cys Tyr Arg
Tyr Met Gln Tyr
Tyr Met Tyr Gln
Tyr Gln Met Tyr
Tyr Gln Tyr Met
Tyr Arg Cys Tyr
Tyr Arg Tyr Cys
Tyr Tyr Cys Arg
Tyr Tyr Met Gln
Tyr Tyr Gln Met
Tyr Tyr Arg Cys
Atogepant
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CD - Calcitonin gene-related peptide (cgrp) antagonists C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent
1-[2-[4-[(4-Methoxyphenyl)-oxomethoxy]phenyl]ethyl]-2-[[oxo-[4-(trifluoromethyl)phenyl]methyl]amino]-5-benzimidazolecarboxylic acid
C32H24F3N3O6 (603.1617120000001)
3-chloro-2-[(3R)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(pyridin-3-ylmethyl)benzamide
Draflazine
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents
1-[[2-(4-chlorophenyl)cyclopropyl]methoxy]-3,4-dihydroxy-5-[(E)-3-imidazo[4,5-b]pyridin-1-yl-3-phenylprop-2-enoyl]oxycyclohexane-1-carboxylic acid
platensimycin B4
C30H37NO12 (603.2315642000001)
A monosaccharide derivative of platensimycin isolated from Streptomyces platensis.
3alpha,17alpha-dihydroxy-5beta-androstane-11-one-17beta-carboxylate 3-O-(3-sulfo-beta-D-glucuronate)
1-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
N-[(5S,6R,9R)-8-(1,3-benzodioxol-5-ylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1,3-benzodioxole-5-carboxamide
C33H37N3O8 (603.2580522000001)
2-[(2R,4aS,12aS)-8-[(4-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-naphthalen-1-ylacetamide
1-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
1-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea
5-aminopentyl beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranuronosyl-(1->4)-beta-D-glucopyranoside
Adagrasib
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].
3-[(3-{5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl}-1-hydroxypropylidene)amino]-2-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoic acid
C30H37NO12 (603.2315642000001)
(1s,3r,5s,7r,9s,10r,12r,14r,15s,18r,19r,20r,22s,23r)-10,20,22-trihydroxy-7,18-dimethyl-19-(5-oxo-2h-furan-3-yl)-5'h-4,6,11-trioxaspiro[hexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosane-9,2'-[1,3]thiazole]-14-carbaldehyde
C31H41NO9S (603.2501896000001)
(1s,4s,7s,9s,10s,25s,26r)-4-hydroxy-7-(hydroxymethyl)-7-methoxy-17,17,24,24-tetramethyl-8,16-dioxa-3,22,28-triazanonacyclo[23.6.1.0¹,²⁸.0³,²⁶.0⁴,⁹.0¹⁰,²⁶.0¹¹,²³.0¹²,²¹.0¹⁵,²⁰]dotriaconta-11(23),12,14,18,20-pentaene-2,5,27-trione
C33H37N3O8 (603.2580522000001)
(1s,3r,5s,7r,9s,10r,12r,14r,15s,18r,19r,22s,23r)-4',10,22-trihydroxy-7,18-dimethyl-19-(5-oxo-2h-furan-3-yl)-5'h-4,6,11-trioxaspiro[hexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosane-9,2'-[1,3]thiazole]-14-carbaldehyde
C31H41NO9S (603.2501896000001)
1,5-dimethyl (2s)-2-[(6as)-5-chloro-9-[(2s,3r)-3-methoxy-2-methylbutanoyl]-6a-methyl-3-[(1e,3s)-3-methylpent-1-en-1-yl]-6,8-dioxofuro[2,3-h]isoquinolin-2-yl]pentanedioate
4-hydroxy-7-(hydroxymethyl)-7-methoxy-17,17,24,24-tetramethyl-8,16-dioxa-3,22,28-triazanonacyclo[23.6.1.0¹,²⁸.0³,²⁶.0⁴,⁹.0¹⁰,²⁶.0¹¹,²³.0¹²,²¹.0¹⁵,²⁰]dotriaconta-11(23),12,14,18,20-pentaene-2,5,27-trione
C33H37N3O8 (603.2580522000001)
3-({3-[(5s)-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl]-1-hydroxypropylidene}amino)-2-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoic acid
C30H37NO12 (603.2315642000001)
4',10,22-trihydroxy-7,18-dimethyl-19-(5-oxo-2h-furan-3-yl)-5'h-4,6,11-trioxaspiro[hexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosane-9,2'-[1,3]thiazole]-14-carbaldehyde
C31H41NO9S (603.2501896000001)
(3s,6s,7r)-6-hydroxy-8-methyl-3-(3,4,5-trimethoxybenzoyloxy)-7-{[(2e)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-8-ium-8-olate
C30H37NO12 (603.2315642000001)
10,20,22-trihydroxy-7,18-dimethyl-19-(5-oxo-2h-furan-3-yl)-5'h-4,6,11-trioxaspiro[hexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosane-9,2'-[1,3]thiazole]-14-carbaldehyde
C31H41NO9S (603.2501896000001)